Inhibition of p53 by either by knockdown or by pharmacologic interventions sensitizes the cancer cells to type I ferroptosis inducer (erastin and SAS), but not to type II ferroptosis inducer (RSL3 and FIN56). The gene discussed is TP53; the disease is cancer.